Curriculum Vitae

Abolfazl Iranikhah

Biographical:

Name: Abolfazl

Family Name: Iranikhah

Date of birth: Jan 4, 1966

Place of birth: Iran, Qom

Nationality: Islamic Republic Of Iran

Education:

Subspecialty: Pediatric Gastroenterology and Hepatology Tehran University Of Medical Sciences 2004-2006

Specialty: Pediatrics Tehran University Of Medical Sciences 1997-2000

General Medicine: Tehran University Of Medical Sciences & Hormozgan University of Medical Sciences1988-1995

Honors:

First rank in the Nationwide Board of Pediatric Gastroenterology and Hepatology 2006

Academic Position:

Assistant Professor of Pediatrics- Qum university of Medical Sciences 2004-2006

Assistant Professor of Pediatric Gastroenterology and Hepatology-Qum university of Medical Sciences Present

Fellow of Pediatric Gastroenterology and Hepatology Tehran University of Medical Sciences 2004-2006

Management positions:

-Manager of Emergency Center of Qom University of Medical Sciences 1996-97

-Manager of Trauma and Surgical Center of Qom University of Medical Sciences 2001-2002

- Vice Chancellor for Health - Qom University of Medical Sciences 2002-2004

-The Deputy of the Minister of Health in Headquarters of Inspection in Qom 2003-2004

Membership in Scientific Professional Organizations

Iranian society of Pediatric Gastroenterology and Hepatology since 2004

Iranian society of Gastroenterology and Hepatology since 2004

Administrative Activities and Teaching Experiences:

1.Research studies in Upstate Medical University, New York, USA, 2009

2. Research Studies as Complementary Education in the UK Universities and Medical Centers. (London ,Birmingham, Manchester) 2007

3. Lecture: “Cyclosporine as a therapeutic agent in AIH”. UK-Children’s Hospital of Birmingham- Liver team of Professor Kelly. 2007

4. Several Teaching lectures about GI diseases, Hepatology and Nutrition 2005-2006 Tehran University Of Medical Sciences, Childrens Hospital of Medical Center

5. Annual lectures in Symposiums of GI & Nutrition in Tehran since 2007

6. Several Poster Presentations in International GI Congresses in Iran, European Countries (UEGW) and NASPGHAN in the USA

Some of Publications and Theses:

Liver Copper Storage Disease in Children with Cryptogenic Chronic 1. Ahmad Khodadad, , ,Abolfazl Iranikhah Liver DiseaseVol ojs.hbi.ir Najafi sani Nasseri, Mehry-SeyedMohammadMahdi Mir11, No 2 (2006)

2. Assessment of the effects and safety of Cyclosporine as a therapy for Autoimmune Hepatitis. Abolfazl Iranikhah, Mehri Najafi sani,… ojs.hbi.ir › Home › Vol 15, No 4 (2011) › Iranikhah

3. Protein losing enteropathy as a sole manifestation of Intestinal Non-Hodgkins Lymphoma. Iranikhah A, Farahmand F,Scientific Journal of the Iranian Association of Gastroenterology and Hepatology Vol.10, No. 4, winter 2005

4. Stool antigen tests for the detection of Helicobacter pylori in children

. Mahvari M, Heiari A, Saneian H, S Sarkeshikian, Ghadir MR, Iranikhah A42.-2013 Apr;23(2):138 tr.Iran J Pedia

5.Azithromycin based triple therapy versus standard clarithromycin based.

triple therapy in eradication of Helicobacter pylori infection in Iran: a

randomized controlled clinical trial The Turkish Journal of Gastroenterology

7102 ,Volume 24, No 1, Pages 10-14

Seyed Saeid SARKESHIKIAN1, Abolfazl IRANIKHAH2, Mohammad Reza

GHADIR1

Furazolidone, amoxicillin and omeprazole with or without bismuth for 6.

eradication of Helicobacter pylori in peptic ulcer disease

Ghadir MR1, Shafaghi A2, Iranikhah A1, Pakdin A3, Joukar F4, Mansour -

Ghanaei F1 The Turkish Journal of Gastroenterology 2011, Volume 22, No 1 ,

Page(s) 1-5

7.Unexplained infertility as primary presentation of celiac disease, a case report

and literature review .

F. , Rahimabadi-M. Sedigh, F. Joukar, M. Jandaghi, A. Iranikhah, M. GhadirGhanaei-Mansour

Iranian Journal of Reproductive Medicine 2011;9(2): 135-140 .

8.Comparison of two most prescribed H. pylori eradication regimens in Zahedan

... Farzinezhad, Saeed Yazdani, Seyed Saeed Sarkeshikian, Abolfazl Iranikhah .

www.iaghcongress.org › ... .:IAGH:.Iranian Association of -Poster Presentation

ICGH 2012 › Home

Assessment of the effects and safety of cyclosporine as a therapy for autoimmune hepatitis

Background /Aims:

The current immunosuppressive treatment of patients with autoimmune hepatitis (AIH) consists of prednisolone and azathioprine. High doses of prednisolone used to obtain the remission of disease are not universally effective and have serious adverse effects. Some authors provide data of the therapy of AIH in children and adults with cyclosporine (Neoral) should corticosteroid therapy turn out ineffective. Preliminary results using cyclosporine in a small group of patients have shown that this drug appears to be a good substitute for corticosteroids. To assess efficacy and safety of cyclosporine in induction of remission in children with AIH this study was performed.

Method:

This is a case series, interventional clinical trial involving children with AIH. 11children with a median age of 9 years 3 months, 9 girls and 2 boys were recruited, who according to international criteria were considered as having definite AIH. Cyclosporine alone was administered at a dosage of 3.5-5 mg/kg in 3 daily doses for 5 months, followed by low dose of prednisolone(o.3 mg/kg/d) for one month then combined low doses of prednisolone and azathioprine(1.5 mg/kg/d in 2 doses). Cyclosporine was discontinued after 7 months. Biochemical remission of the disease was established by the follow- up of serum transaminase activity levels. Growth parameters including Z-scores for height and weight and adverse effects of the treatment were recorded.

Results:

One patient was withdrawn from the study because of non- compliance .Of the 10 remaining patients, 9 normalized alanine aminotrasnferase(ALT) activity levels by 4 months and all the patients by

9 months of treatment. Adverse effects of cyclosporine were mild and disappeared during weaning off the medication.

Conclusion:

Cyclosporine induced the biochemical remission of the hepatic inflammatory / necrotic process in children with autoimmune hepatitis, with few and well – tolerated adverse effects. Longer follow-up of the patients is necessary to establish possible long-term toxicity of cyclosporine and randomized controlled trials are warranted.

Key words:

Autoimmune hepatitis; cyclosporine; treatment